Management of Pancreatic Cancer and Cholangiocarcinoma.

Format:

Book

Author/Creator:

Isayama, Hiroyuki.

Contributor:

Nakai, Yousuke.

Sasaki, Takashi.

Language:

English

Genre:

Electronic books.

Physical Description:

1 online resource (318 pages)

Place of Publication:

Singapore : Springer Singapore Pte. Limited, 2021.

System Details:

text file

Contents:

Intro

Preface

Contents

Part I: Current Topics in Epidemiology and Examinations of Pancreatic Cancer and Cholangiocarcinoma

1: Risk Factors for Pancreatic Cancer and Cholangiocarcinoma

1.1 Risk Factors for Pancreatic Cancer

1.1.1 Introduction

1.1.2 Genetic Factors

1.1.3 Pancreatic Disorders (Cystic Lesions and Chronic Pancreatitis)

1.1.4 Epidemiological Factors

1.1.5 Microbiome

1.1.6 Discussion

1.2 Risk Factors for Cholangiocarcinoma

1.2.1 Introduction

1.2.2 Microbiome (Infectious Diseases)

1.2.3 Genetic Factors

1.2.4 Pancreatobiliary and Inflammatory Disorders

1.2.5 Epidemiological Factors

1.2.6 Discussion

References

2: Detection Strategies and Examination of Early Pancreatic Cancer

2.1 Introduction

2.2 Clinical Features and Image Findings of Early-Stage PC

2.3 Cytological Diagnosis of Early-Stage PC

2.4 Pathological Features of Early-Stage PC

2.5 Statements and Detection Strategies of Early-Stage PC in Japan

2.6 Collaborations Between Specialists and General Practitioners for Early-Stage PC in Japan

References

3: Biomarkers for Pancreatic Cancer and Cholangiocarcinoma

3.1 Introduction

3.2 Currently Used Biomarkers for PDAC and CCA

3.3 Other Protein Markers for PDAC and CCA

3.4 Circulating Tumor Cells

3.5 Extracellular Vesicles

3.6 Biomarker-Based Selection of Targeted Therapies

3.7 Conclusion and Future Perspectives

4: Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma

4.1 Introduction

4.2 Features of Two Reimbursed CGP Tests

4.3 Required Tissue Samples

4.4 Liquid Biopsy

4.5 Eligible Patients for CGP Test and Optimal Timing of Its Application

4.6 Clinical Benefit of CGP Tests in Pancreatic Cancer

4.7 Clinical Benefit of CGP Tests in Biliary Tract Cancer

Part II: Anti-cancer Treatments for Pancreatic Cancer

5: Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

5.1 Introduction

5.2 Metastatic Pancreatic Cancer

5.2.1 FOLFIRINOX

5.2.2 Gemcitabine Plus Nab-Paclitaxel

5.2.3 Selection Between FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel

5.2.4 Intraperitoneal Chemotherapy in Patients with Peritoneal Dissemination

5.3 Locally Advanced Pancreatic Cancer

5.4 The Role of Monotherapy

5.5 Second-Line Chemotherapy

5.6 Future Perspective

6: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer

6.1 Introduction

6.2 Preoperative Estimation for Surgical Resectability

6.3 Potentially Resectable Tumors

6.4 Prospective Studies for NAT and Adjuvant Therapy

6.5 Optimal Agent or Regimens for NAT for Potentially Resectable PA

Notes:

Description based upon print version of record.

6.6 Optimal Regimens for NAT: Chemotherapy or CRT?

Other Format:

Print version: Isayama, Hiroyuki Management of Pancreatic Cancer and Cholangiocarcinoma

ISBN:

9789811628702

981162870X

OCLC:

1261366758

Access Restriction:

Restricted for use by site license.